QT PROLONGATION WITH THE USE OF ORAL ARTEMETHER-LUMEFANTRINE COMBINATION THERAPY

Authors

  • Muhammad Sadiq
  • Muhammad Abbas Khan
  • Umair Ali
  • Adnan Zar
  • Syed Aman Shah
  • Sifat Ullah

DOI:

https://doi.org/10.47144/phj.v52i2.1746

Abstract

Objective: To determine the frequency of patients developing QT prolongationwith the use of oral Artemether-Lumefantrine (AL) combination therapy.

Methodology: This cross sectional study was conducted in general medicinedepartment of Khyber Teaching Hospital from January to December 2018. A totalof 133 patients were selected on basis of consecutive (non-probability)sampling. All adult patients (irrespective of gender) presenting with high gradefever having positive blood smear (thick and thin blood films) for plasmodiumfalciparum and not taken any antimalarial treatment in the preceding seven dayswere included in the study. All information was entered in pre designed proforma.

Results: Total 133 patients were including. Mean age was 30 ± 3.18 years.About 72% patients were males while 28% patients were female. Prolongcorrected QT interval among 133 patients were analyzed, and no patient withprolonged corrected QT interval was observed.

Conclusion: It can be concluded that AL is a safe drug combination for thetreatment of falciparummalaria with negligible adverse effects on QT profile.

Key Words: QT Prolongation, Plasmodium falciparum, Malaria, Artemether,Lumefentarine.

Downloads

Download data is not yet available.

Downloads

How to Cite

1.
Sadiq M, Khan MA, Ali U, Zar A, Shah SA, Ullah S. QT PROLONGATION WITH THE USE OF ORAL ARTEMETHER-LUMEFANTRINE COMBINATION THERAPY. Pak Heart J [Internet]. 2019Sep.3 [cited 2024Nov.23];52(2). Available from: https://pakheartjournal.com/index.php/pk/article/view/1746

Issue

Vol. 52 No. 2 (2019): Pakistan Heart Journal

Section

Original Article

License

When an article is accepted for publication in the print format, the author will be required to transfer exclusive copyright to the PHJ and retain the rights to use and share their published article with others. However, re-submission of the full article or any part for publication by a third party would require prior permission of the PHJ.

Online publication will allow the author to retain the copyright and share the article under the agreement described in the licensing rights with creative commons, with appropriate attribution to PHJ. Creative Commons attribution license CC BY 4.0 is applied to articles published in PHJ https://creativecommons.org/licenses/by/4.0/